Watch for the official FDA meeting minutes within the next 30 days, which will confirm the exact Phase 3 design and endpoints. Any mention of a potential accelerated approval pathway or reduced trial size would be a further catalyst. Also monitor for any strategic partnership announcements, as the CEO explicitly signaled intent to explore partnering.
Price Chart
Executive Summary
Radiopharm Theranostics announced successful completion of an End-of-Phase 2 meeting with the FDA for RAD101, its investigational imaging agent for brain metastases. The FDA provided a clear framework for the pivotal development program, and the company is initiating Phase 3 readiness activities while awaiting formal meeting minutes within ~30 days. This is a positive regulatory milestone for a clinical-stage biotech with no approved products, but the stock has historically declined on prior positive news, warranting caution.
Key Facts
- Completed End-of-Phase 2 meeting with FDA for RAD101, an imaging agent for brain metastases
- FDA provided clear framework for pivotal clinical development plan
- Phase 2b trial showed 93% concordance with MRI, meeting primary endpoint
- FDA Fast Track Designation previously granted for RAD101
- Partnership with Siemens Healthineers for manufacturing and distribution of RAD101 for Phase 3
- Formal FDA meeting minutes expected within approximately 30 days
- Company evaluating potential strategic partnering opportunities for RAD101
- Over 300,000 patients diagnosed annually with cerebral metastases in the U.S.
Financial Impact
No financial figures disclosed; clinical-stage company with no approved products or revenue
Risk Factors
- FDA meeting minutes could contain unexpected requirements or additional trial design burdens
- Phase 3 trial execution and enrollment risks remain significant
- Company has no approved products and no disclosed revenue; cash runway and financing needs are not addressed in this filing
- Historical stock performance on prior positive news has been negative, suggesting potential sell-the-news pattern
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-106652 |
| Document: ea0307670-6k_radiopharm.htm | 0001213900-26-106652 |
| Document: 0001213900-26-106652-index-headers.html | 0001213900-26-106652 |
| Document: 0001213900-26-106652-index.html | 0001213900-26-106652 |
| Document: 0001213900-26-106652.txt | 0001213900-26-106652 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9600 (−3.03%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9600 (−11.11%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9600 (−24.41%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9600 (−35.14%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9600 (−40.74%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9600 (+38.93%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9600 (−41.82%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9600 (−52.24%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9600 (−51.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers